Phenylketonurias
Pipeline by Development Stage
Rare Diseases is a $21.9B market dominated by a single blockbuster (ELIQUIS), with moderate growth and high consolidation among top-tier pharma players.
Key Trends
- Market concentration: One product (ELIQUIS) represents 83% of market spending
- Complement inhibitors and enzyme replacement therapies gaining momentum
- Active pipeline with 1,790 trials, predominantly Phase 2-3 stage
Career Verdict
Yes, if you seek stability and commercial opportunity with major pharma; proceed cautiously if you want pipeline upside or innovation-driven roles.
AI-generated market analysis based on FDA, CMS, ClinicalTrials.gov, and hiring data
Market Leaders
| # | Product | Company | Revenue | Share | Stage | Trend | LOE |
|---|---|---|---|---|---|---|---|
| 1 | ELIQUIS (apixaban) | Bristol Myers Squibb | $18.3B | 83% | LAUNCH | Stable | 15.0yr |
| 2 | XIFAXAN (rifaximin) | Bausch Health | $1.1B | 5% | LOE_APPROACHING | Declining | |
| 3 | BRILINTA (ticagrelor) | AstraZeneca | $692M | 3% | PEAK | Stable | 10.2yr |
| 4 | TYVASO DPI (treprostinil) | United Therapeutics | $437M | 2% | PEAK | Stable | 15.7yr |
| 5 | STRENSIQ (asfotase alfa) | AstraZeneca | $259M | 1% | PEAK | Stable |
Drug Class Breakdown
Mature, patent-protected until 2041
Mixed—includes LOE-approaching products
Peak sales, LOE 2036
Stable, long patent protection
Emerging class, no LOE data available
Niche market, specialized patient populations
Career Outlook
StableThe rare disease market is stable but mature, with job growth concentrated in commercial and medical affairs rather than R&D innovation. Consolidation among top pharma (AstraZeneca, BMS, Amgen) limits opportunities for mid-tier companies, but specialist biotech firms show hiring momentum. Patent cliff risk for ELIQUIS (2041) will create restructuring opportunities and potential job flux in downstream years.
Breaking In
Target commercial or quality assurance roles at AstraZeneca, Capricor, or Amgen to build market knowledge; rare disease expertise is portable and valued across therapeutic areas.
For Experienced Professionals
Seek regulatory or medical affairs leadership roles where salary ceiling is highest ($243K-$257K); consider biotech firms like Insmed or Krystal for upside if pipeline approvals accelerate.
In-Demand Skills
Best For
Hiring Landscape
Rare disease hiring is concentrated in commercial roles (75 jobs at $215K avg) and medical affairs (16 jobs at $243K avg), reflecting a mature market's focus on market access and HCP engagement. Top hiring companies include AstraZeneca (38 jobs) and emerging biotech players like Capricor Therapeutics (30 jobs). Department salaries range from $114K-$257K, with regulatory affairs commanding premium compensation.
Top Hiring Companies
By Department
Commercial and regulatory roles offer strong salaries and growth; R&D hiring is minimal (10%), reflecting a consolidation and maturity phase in the market.
Competitive Landscape
5 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
Showing 15 of 19 trials with date data
Clinical Trials (19)
Total enrollment: 1,310 patients across 19 trials
Immune Modulation During Palynziq® Treatment in Adults (IMPALA)
Study of Phenoptin to Increase Phenylalanine Tolerance in Phenylketonuric Children on a Phenylalanine-restricted Diet
A Phase 3, Multicenter, Open-Label Extension Study of Phenoptin in Subjects With PKU Who Have Elevated Phenylalanine Levels
Study to Evaluate the Safety and Efficacy of Phenoptin™ in Subjects With Phenylketonuria Who Have Elevated Phenylalanine Levels
Study to Evaluate the Response to and Safety of an 8-Day Course of Phenoptin™ Treatment in Subjects With Phenylketonuria
AAV Gene Therapy Clinical Study in Adult Classic PKU (PHEdom)
Safety and Efficacy Study of NGGT002 in cPKU Adult Subjects
Development of Novel Psychological Assessment Tools and Anxiety Intervention for Phenylketonuria
PheCheck Feasibility Study
Additional Dietary Large Neutral Amino Acids (LNAA) for Improved Symptoms in Adult Classical Phenylktonuria (PKU)
Preliminary Study of Brain Effects of Palynziq-Related Changes in Phenylalanine in Individuals With PKU
A Prospective Clinical Study of Phenylketonuria (PKU)
Nutritional Impacts of Palynziq on Patients With Phenylketonuria (PKU)
Nutrition Status of Adults With PKU Before and During Treatment With Pegvaliase
Nutrition Status of Adults Treated With Pegvaliase
Evaluation of PKU Sphere
PKU Skin Stripping
Testing of Four Home Phenylalanine Monitoring Prototype Devices
Bone Mineral Density in Adults With Hyperphenylalaninemia
Related Jobs in Rare Diseases
Ingénieur Industrialisation Expérimenté - F/H
Director, Medical Writing
Senior Manager, International Accounting
LIMS System & Data Specialist II
Regional Business Director, Rare Disease - Northeast
Director, Quality Assurance & Quality Systems
Phase Legend
Key Insights
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.